SCLEROTHERAPY PLUS OCTREOTIDE VERSUS SCLEROTHERAPY ALONE IN THE MANAGEMENT OF GASTRO-OESOPHAGEAL VARICEAL HEMORRHAGE
AbstractBackground: There are different ways for controlling oesophageal variceal bleed which include pharmacological and endoscopic methods. In this study we compare efficacy of octreotide (50 g/hr for 48 hours) combined with sclerotherapy versus sclerotherapy alone in patients with acute bleeding from gastro-oesophageal varices (GOV). Methods: It was a randomized clinical controlled trial conducted at Aga Khan University Hospital, Karachi, from January1997 to December 1998. We evaluated the role of octreotide (50 g/hr for 48 hours) combined with sclerotherapy versus sclerotherapy alone in a total of 105 adult cirrhotic patients who had acute bleeding from GOV. Patients were assigned to receive octreotide plus sclerotherapy or sclerotherapy alone. Primary outcome measure was 5-day survival without rebleeding. The hospital stay in days and blood transfusion requirements were also compared in the combined treatment group versus sclerotherapy alone group. Results: Initial control of bleeding was achieved in 46/51 (90.2%) patients who received combined treatment compared to 41/54 (75.9%) patients (p=0.05) in sclerotherapy alone group. Rebleeding after the first 48 hours was less in the octreotide treated patients 2/46 vs. 8/41 patients (p=0.003). The octreotide treated patients had a better short term (5 days) survival without rebleeding 44/51 vs. 33/54 (p=0.003) and shorter hospital stay, 5.31 ± 3.87 days vs. 6.63 ± 3.86 (p=0.008) as compared to sclerotherapy alone group. The blood transfusion requirement was also less in the combined treatment group 3.88 ± 2.80 vs. 5.37 ± 3.15 units (p=0.002). Conclusion: 1) The combination of sclerotherapy and octreotide infusion over 48 hours is more effective than sclerotherapy alone in the treatment of acute variceal bleeding and prevention of early rebleed in cirrhotic patients. 2) It leads to shorter hospital stay and 3) less blood transfusion requirements. 4) Although early survival without rebleeding is improved, the overall mortality at the end of hospitalization period is similar in the two groups of treated patients.Key words: Varices, Esophageal, Sclerotherapy, Octreotide, Cirrhosis.
D'Amico G, Morabito A, Pagliaro L, Marubini E. Liver study group of V Cervello Hospital. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 31:468-75.
García-Pagá JC, Terés J, Calvet X, Bosch J, Rodés J. Factors which influence the prognosis of the first episode of variceal hemorrhage in patients with cirrhosis. In: Bosch J, Rodés J (eds) Recent advances in the pathophysiology and therapy of portal hypertension. Serono Simp Rev 1989; 22:287-302.
De Dombal FT, Clarke JR, Clamp SE, Malizia G, Kotwal MR, Morgan AG. Prognostic factors in upper G.I. bleeding. Endoscopy 1986; 18: 6-10.
Cardin F, Gori G, McCormick PA, Burroughs AK. A predictive model for every early rebleeding from varices. Gut 1990; 31:A1204 (abstract)
Sung JJ, Chung SC, Yung MY, Lai CW, Lau JY, Lee YT et al. Prospective randomised study of effect of octreotide on rebleeding from esophageal varices after endoscopic ligation. Lancet. 1995; 23-30; 346(8991-8992): 1666-69.
D'Amico G, Morabito A, Pagliaro L, Traina M, Montalbano L. Six week prognostic indicators in upper gastrointestinal hemorrhage in cirrhosis. Frontiers Gastrointest Res 1986; 9:247-52.
Terblanche J, Burroughs AK, Hobbs KEF. Controversies in the management of bleeding esophageal varices. N Engl J Med 1989; 320:1393-98.
Burroughs AK, Hamilton G, Phillips A, Mezzanotte G, McIntyre N, Hobbs KEF. A comparison of sclerotherapy with staple transection of the esophagus for the emergency control of bleeding from esophageal varices. N Engl J Med 1989; 321:857-62.
Bosch J, Garcia Pagan JC. Prevention of variceal rebleeding. Lancet 2003; 361 (9361): 952-54.
McKee R. A study of octreotide in oesophageal varices. Digestion 1990; 45:60-65.
MacCormick PA, Biagini MR, Dick R, Greensland L, Chin J, Cardin F, et al. Octreotide reduces azygos blood flow in cirrhotic patients with portal hypertension. Eur J Gastroenterol Hepatol 1990; 2:489-92.
Ludwig D, Schadel S, Burning A, Schiefer B, Stange EF. 48 hour hemodynamic effects of octreaotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double blind, placebo controlled study. Dig Dis Sci. 2000; 45 (5): 1019-27.
Nevens F, Van Steenbergen W, Yap SH, Feverly J. Assessment of Variceal pressure by continuous non-invasive endoscopic registration: A placebo controlled evaluation of the effect of terlipressin and octreotide. Gut 1996; 38(1): 129-34.
Hwang JS, Lin CH, Chang CF. A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding. J Hepato l1992; 16:320-25.
Campisi C, Padula P, Peressini A, Boccardo F, Biraghi M, Casaccia M. Emorragie digestive alte confronto fra terlipressina e octreotide. Minerva Chir 1993; 48:1-5.
Silvain C, Carpentier S, Sautereau D, Czernichow B, Metreau JM, Fort E, et al. Terlipressin plus transdermal nitroglycerin vs. octreotide in the control of acute bleeding from esophageal varices: a multicenter randomized trial. Hepatology 1993; 18:61-65.
Sung JJ, Chung SCS, Lai CW, Chan FKL, Leung JWC, Yung MY. Octreotide infusion for emergency sclerotherapy of variceal hemorrhage. Lancet 1993; 342:637-41.
Jenkins SA, Copeland G, Kingsworth A, Shields R. A prospective randomized controlled clinical trial comparing Sandostatin and injection sclerotherapy in the control of acute variceal haemorrhage: an interim report. Gut 1992; 33:F221 (abstract).
Besson I, Ingrand P, Person B, Boutroux D, Heresbach D, Bernard P, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995; 333:555-60.
Zuberi BF, Baloch Q. Comparison of endoscopic variceal sclerotherapy alone and in combination with octreotide in controlling acute variceal hemorrhage and early rebleeding in patients with low risk cirrhosis. Am J Gastroenterology 2000; 95 (3): 768-71.
Freitas DS, Sofia C, Pontes JM, Gregorio C, Cabral JP, Andrade P et al. Octreotide in acute bleeding esophageal varices: A randomized study. Hepatogastroenterology 2000; 47(35): 1310-14.
Thomsen BL, Moller S, Sorensen TI. Copenhagen Esophageal Varices Sclerotherapy project. Optimized analysis of recurrent bleeding and death in patients with cirrhosis and esophageal varices. J Hepatol 1992; 21:367-75.
Moller S, Sorensen TI, Tygstrup N. Copenhagen Esophageal Varices Sclerotherapy Project. Who benefits from endoscopic sclerotherapy of bleeding oesophageal varices? Proposal for different indications. J Hepatol 1992; 15:184-91.
Shields R, Jenkins SA, Baxter JN, Kingsnorth A, Ellenbogen S, Martin C, et al. A prospective randomized controlled trial comparing the efficacy of somatostatin with injection sclerotherapy in control of bleeding esophageal varices. J Hepatol 1992; 16:128-37.
Jenkins SA, Shields R, Davis M, Elias E, Turnbull AJ, Bassendine MF et al. A Multicentre randomized trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal hemorrhage. Gut 1997; 41:526-33.
Bilodozola M, Kravetz D, Argonz J, Romero G, Suarez A, Jmelnitzky A, et al. Efficacy of octreaotide and sclerotherapy in the treatment of acute variceal bleeding in cirrhotic patients. A prospective, Multicentric and randomized clinical trial. Scan J Gastroenetrol 2000;35(4):419-25.
Khan UI, Hameed K, Farooqi JI, Khan MI, Shah S. Efficacy of low dose intravenous octreotide for 24 hours in acute variceal bleed. JCPSP 2001;11(8):478-81.
Primignani M, Capria A, Andreoni B, Carpinelli L, Rocchi G, Lorenzini I, et al. Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: A randomized, double blind, placebo controlled, multi-center trial. New Italian Endoscopy Club. Hepatology 1995; 21(5): 1322-7